This activity leads to the inhibition of downstream pERK activation, showcasing antitumor effects in cancer mouse models.498 Remarkably, ASP3082 targets KRAS G12D for degradation, thereby inhibiting downstream molecular signaling and apoptotic respons, and displays dose-dependent antitumor activity across multiple cancer models with the KRAS G12D mutation.499 A Phase I clinical trial is currently ongoing to evaluate this innovative treatment. The gene discussed is KRAS; the disease is cancer.